FENNEC (FENC) CCO Terry L. Evans Receives 168 Shares

What Happened
Terry L. Evans, Chief Commercial Officer of Fennec Pharmaceuticals (FENC), acquired 168 shares on 2026-08-31 via an award/other acquisition. The shares were reported at $0.00 per share (total reported cash = $0) and represent the release of restrictions from a prior award.

Key Details

• Transaction date and price: 2026-08-31; 168 shares at $0.00 per share (total $0).
• Transaction code: A (award, grant, or other acquisition).
• Footnote: F1 — these shares were released from restriction from shares awarded on 2025-03-28.
• Shares owned after transaction: Not disclosed in this filing.
• Filing: Form 4 filed with accession 0002043317-26-000012 on 2026-08-31; no indication in the filing that it was late.

Context
This was a release/vesting of previously awarded restricted shares (compensation), not an open-market purchase or sale. Such vesting events reflect executive compensation and do not by themselves indicate a buy/sell signal about the insider's view of the stock. (Note: vesting is typically a taxable event even if no cash changes hands.)